Cefepime versus vancomycin plus netilmicin therapy for continuous ambulatory peritoneal dialysis-associated peritonitis

American Journal of Kidney Diseases

Volumn 38, Issue 1, 2001, Pages 127-131

  Wong, Kim Ming ^a   Chan, Yiu Han ^a   Cheung, Chi Yuen ^a   Chak, Wai Leung ^a   Choi, Koon Shing ^a   Leung, Shuk Hing ^a   Leung, Janet ^a   Chau, Ka Foon ^a   Tsang, Dominic N C ^a   Li, Chun Sang ^a  

^a QUEEN ELIZABETH HOSPITAL   (Hong Kong)

Author keywords

Cefepime; Continuous ambulatory peritoneal dialysis (CAPD); Intraperitoneal (IP); Peritonitis

Indexed keywords

CEFEPIME; NETILMICIN; VANCOMYCIN;

ADULT; AGED; ARTICLE; BACTERIAL GROWTH; BACTERIAL PERITONITIS; BACTERIUM CULTURE; CLINICAL TRIAL; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG SAFETY; FEMALE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HEALTH CARE COST; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL;

EID: 0034974163     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/ajkd.2001.25205     Document Type: Article

References (17)

1. Pharmacokinetics of cefepime in patients undergoing continuous ambulatory peritoneal dialysis
2. Use of intra-peritoneal (IP) cefepime as monotherapy in the treatment of CAPD peritonitis
3. Stability of cefepime in peritoneal dialysis solution
4. High-pressure liquid chromatographic analysis of BMY-28142 in plasma and urine
5. Effect of aminoglycoside use on residual renal function in peritoneal dialysis patients
6. Detection of vancomycin resistance in Enterococcus species
7. Peritoneal dialysis related peritonitis treatment recommendation: 1996 Update
8. Intraperitoneal once daily dose of cefazolin and gentamicin for treating CAPD peritonitis
9. The activity of BMY 28142, a new broad spectrum beta-lactamase stable cephalosporin
10. Selection and characterization of cefepime-resistant gram-negative bacteria
11. Safety of cefepime, a new extended-spectrum parenteral cephalosporin
12. Cefepime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use
13. Cefepime-related neurotoxicity in a haemodialysis patient
14. Disposition of cephalosporin cefepime in normal and renal impaired subjects
15. Intermittent versus continuous antibiotics for PD-related peritonitis
16. Cost-effectiveness analysis of cefepime compared with ceftazidime in intensive care unit patients with hospital-acquired pneumonia